Mesothelioma and Radical Surgery (MARS) Trial
There are currently differing opinions as to whether radical extrapleural pneumonectomy (EPP) is the best choice of treatment for patients with early stage mesothelioma. Surgery to date has been possible only for a relatively small number of patients based on advanced stage at the time of presentation, chemotherapy drugs have shown limited activity in controlling the disease and radiotherapy has been most often been palliative in nature.
The MARS study is a randomized trial in which one group of participants would receive chemotherapy, then EPP, then radiotherapy. The second group of patients would receive other types of aggressive therapy, but would not receive EPP.
The goal of this trial is to determine whether extrapleural pneumonectomy in conjunction with adjuvant chemotherapy and radiotherapy offers benefit to the patient in terms of life expectancy and quality of life as compared to other standard therapies, and also to weigh the potential benefits against surgical risk.
The first patients to be enrolled in this program will be from the United Kingdom, however, worldwide participants may be entered as the trial proceeds. Patient selection is on the recommendation of their doctor.
If you are interested in participating in this trial, you should ask your doctor for more information on whether it may be suitable in your particular case.